Most recent by Jai N. Patel, PharmD, BCOP, CPP
Personalized approach must guide extended aromatase inhibitor therapy for breast cancer
Approximately 75% of patients with breast cancer have hormone receptor–positive disease, in which growth and replication depends on estrogen signaling.
Ability to harness immune system may provide urgently needed therapies for pancreatic cancer
In contrast to the steady increase in survival for most cancers, advances have been slow for pancreatic cancers.
Navigating the National Health System: A personal experience
An experience abroad had me contemplating the state of our health system in the United States and the implications of nationalized health care.
Management of chemotherapy-induced peripheral neuropathy requires personalized approach
Chemotherapy-induced peripheral neuropathy is a frequent and debilitating adverse effect of commonly used chemotherapy agents.
Biosimilars may expand drug access, reduce costs, but still much to learn
Cancer is the major indication for six of the 10 best-selling biological products.
Effective methods exist to prevent, treat therapy-related dermatologic adverse events
Skin and mucosal reactions to oral chemotherapeutic agents are common complications of cancer treatment and may severely impair patients’ quality of life.
Host genetic variants as predictors of chemotherapy-related toxicity in children with ALL: Personalizing the benefit–risk balance
Acute lymphoblastic leukemia is the most common childhood cancer.